|
|
||||||||

* Centre National de la Recherche Scientifique-Unité Propre de Recherche 2163, Centre-Hopital-Universitaire Purpan, Toulouse, France; and
Unité Mixte Recherche 2587, Centre National de la Recherche Scientifique-Pierre Fabre, Toulouse, France
Syngenic C57BL/6 mice (H-2b) vaccinated with mitomycin C-treated L12R4 T lymphoma cells develop protective immunity toward the MHC class II-negative tumor cells. In the present study, we characterize the nature, mode of function, and specificity of the effector cells in this immunity. These cells are TCR-specific CD8+ T lymphocytes with effector function in vitro as well as in vivo upon transfer to naive mice. They produce high levels of IFN-
and TNF-
, but little or no IL-4. By means of TCR
-negative variant L12R4 cells, P3.3, and TCR-V
2 cDNA-transfected and TCR-V
2-expressing P3.3 lymphoma cells, we found that a significant part of the effector T cells are specific for the V
12 region. The growth inhibition of L12R4 cells in vitro was inhibited by anti-H-2, anti-Kb, and anti-Db mAb. Furthermore, vaccination with V
12 peptide p6778, which binds to both Kb and Db MHC class I molecules, induces partial protection against L12R4 T lymphoma cells. Thus, self-reactive TCR-V
-specific, Kb-, or Db-restricted CD8+ T cells mediate inhibition of T cell lymphoma growth in vitro and in vivo.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |